罗格列酮对2型糖尿病合并非酒精性脂肪肝患者瘦素的影响

Effect of rosiglitazone on leptin of type 2 diabetes patients complicated by non alcoholic fatty liver

目的探讨罗格列酮对2型糖尿病合并非酒精性脂肪肝患者瘦素水平的影响。方法60例2型糖尿病合并非酒精性脂肪肝患者分为治疗组和对照组,治疗组使用罗格列酮4mg/d,治疗3个月;治疗前后测定空腹、餐后血糖,空腹、餐后胰岛素,血脂、瘦素水平和肝功能,并观察体质指数、腰臀比、胰岛素抵抗指数。结果治疗组瘦素、胰岛素、血糖、甘油三酯、低密度脂蛋白胆固醇明显下降,与对照组相比差异有显著性。结论罗格列酮能降低2型糖尿病合并非酒精性脂肪肝患者的瘦素水平,改善胰岛素抵抗。

Objective To explore the effect of rosiglitazone on leptin of type 2 diabetes patients complicated by non alcoholic fatty liver. Methods 60 type 2 diabetes patients complicated by non alcoholic fatty liver were divided into treatment group and control group. The treatment group was treated with 4mg/d rosiglitazone for 3 months. Fasting and prosnactunal blood glucose,insulin,lipid, leptin and liver function were measured and compared, meanwhile the body mass index, waist/hip ratio and insulin resistance index were observed. Results Leptin level,insulin, blood glucose, triglycerides （ TG ） , and low-density lipoprotein cholesterol （ LDL-C ） were significantly decreased in the treatment group, with significant difference as compared with those of control group. Conclusion Rosiglitazone can reduce the leptin level of type 2 diabetes patients complicated by non alcoholic fatty liver and improve insulin resistance.